Daré Bioscience, Inc. (DARE)
2.03
+0.03
(+1.50%)
USD |
NASDAQ |
Jun 11, 12:39
Daré Bioscience Enterprise Value : 17.78M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 17.78M |
| June 09, 2026 | 16.62M |
| June 08, 2026 | 15.60M |
| June 05, 2026 | 16.04M |
| June 04, 2026 | 20.40M |
| June 03, 2026 | 18.51M |
| June 02, 2026 | 19.82M |
| June 01, 2026 | 20.55M |
| May 29, 2026 | 21.13M |
| May 28, 2026 | 21.86M |
| May 27, 2026 | 23.57M |
| May 26, 2026 | 23.72M |
| May 22, 2026 | 24.17M |
| May 21, 2026 | 24.76M |
| May 20, 2026 | 23.57M |
| May 19, 2026 | 22.37M |
| May 18, 2026 | 20.27M |
| May 15, 2026 | 21.17M |
| May 14, 2026 | 31.51M |
| May 13, 2026 | 31.21M |
| May 12, 2026 | 26.96M |
| May 11, 2026 | 25.35M |
| May 08, 2026 | 28.70M |
| May 07, 2026 | 31.03M |
| May 06, 2026 | 34.67M |
| Date | Value |
|---|---|
| May 05, 2026 | 36.27M |
| May 04, 2026 | 33.94M |
| May 01, 2026 | 22.73M |
| April 30, 2026 | 21.86M |
| April 29, 2026 | 19.24M |
| April 28, 2026 | 20.55M |
| April 27, 2026 | 21.28M |
| April 24, 2026 | 19.38M |
| April 23, 2026 | 19.53M |
| April 22, 2026 | 21.71M |
| April 21, 2026 | 23.02M |
| April 20, 2026 | 30.45M |
| April 17, 2026 | 31.61M |
| April 16, 2026 | 28.27M |
| April 15, 2026 | 14.73M |
| April 14, 2026 | 14.14M |
| April 13, 2026 | 14.58M |
| April 10, 2026 | 15.31M |
| April 09, 2026 | 15.60M |
| April 08, 2026 | 15.60M |
| April 07, 2026 | 14.43M |
| April 06, 2026 | 15.02M |
| April 02, 2026 | 14.00M |
| April 01, 2026 | 16.33M |
| March 31, 2026 | 15.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eton Pharmaceuticals, Inc. | 858.39M |
| ANI Pharmaceuticals, Inc. | 2.161B |
| Corcept Therapeutics, Inc. | 8.056B |
| Assertio Holdings, Inc. | 120.08M |
| Veru, Inc. | 19.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.000M |
| Revenue (Quarterly) | 0.1525M |
| Total Expenses (Quarterly) | 3.152M |
| EPS Diluted (Quarterly) | -0.2066 |
| Gross Profit Margin (Quarterly) | -422.6% |
| Profit Margin (Quarterly) | -1.97K% |
| Earnings Yield | -51.14% |
| Normalized Earnings Yield | -51.14 |